Breast Cancer | Specialty

Dr. Iwase on Elevated Neutrophil to Lymphocyte Ratio to Predict Survival Outcome in TNBC

January 14th 2016

Toshiaki Iwase, MD, Department of General Surgery, Chiba Graduate School of Medicine, Chiba, Japan, discusses a study that examined elevated neutrophil to lymphocyte ratio to predict survival outcomes after recurrence in patients with triple-negative breast cancer.

Hope Rugo on Pembrolizumab's Potential in ER+/HER2- Breast Cancer

January 12th 2016

Hope Rugo, MD, discusses the phase Ib KEYNOTE-028 trial and the impact of its results thus far, as well as the design, findings, and next steps for the trial.

Final USPSTF Guidelines Scale Back Breast Cancer Screening

January 11th 2016

The US Preventive Services Task Force has issued final guidelines that stand by its recommendation that women at average risk of breast cancer should not start routine screenings until they reach age 50 years and that they should then undergo testing every 2 years.

Dr. Mamounas on Future of Surgical Treatments in Breast Cancer

January 5th 2016

Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, shares the future of surgical treatments for patients with breast cancer.

FDA Approves Alcohol-Free Docetaxel Formulation

December 28th 2015

The FDA has approved a non-alcohol formulation of docetaxel as a treatment for patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

Prophylactic Loperamide Reduces Neratinib-Related Diarrhea in HER2+ Breast Cancer

December 22nd 2015

Grade 3 diarrhea occurred in 16% of patients treated with neratinib and prophylactic loperamide, representing a significant reduction compared with phase III findings from the ExteNET trial.

Effective Management and Prevention of Neratinib-Induced Diarrhea

December 18th 2015

Safety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.

Trial Backs 50-Gene Test in Neoadjuvant Setting

December 18th 2015

Neoadjuvant chemotherapy for women diagnosed with breast cancer can help shrink a tumor prior to surgery, which can make the procedure minimally invasive and potentially influence prognosis.

Four FDA Approvals, Two Priority Reviews, and 2015 SABCS Highlights

December 17th 2015

Gargi Basu on Alterations in the Cell Cycle Checkpoint Pathway in Breast Cancer

December 17th 2015

Gargi D. Basu, PhD, senior director of Clinical Curation, Ashion Analytics, discusses a study that examined alterations in the cell cycle checkpoint pathway in patients with breast cancer.

Palbociclib Improves Cell Cycle Control in ER-Positive Breast Cancer

December 14th 2015

Palbociclib enhances cell cycle control when added to anastrazole in the neoadjuvant setting in women with ER-positive primary breast cancer.

FDA Approves Cooling Cap to Reduce Alopecia During Chemotherapy

December 14th 2015

The Dignitana DigniCap Cooling System, a computer-controlled device aimed to reduce the severity and frequency of hair loss in patients who receive neoadjuvant or adjuvant chemotherapy for breast cancer, has been cleared by the FDA as the first cooling cap for use in the United States.

Pembrolizumab Continues to Show Promise in Breast Cancer

December 12th 2015

The PD-1 inhibitor pembrolizumab had an overall response rate of 12% in PD-L1–positive patients with ER-positive/HER2-negative advanced breast cancer.

Neratinib DFS Benefit Sustained in 3-Year ExteNET Update

December 12th 2015

The oral pan-HER TKI neratinib continued to show similar rates of disease-free survival for patients with HER2-positive early-stage breast cancer at a 3-year analysis of the phase III ExteNET trial.

Dr. Patricia Ganz on Anastrozole versus Tamoxifen Side Effects in DCIS Patients

December 11th 2015

Patricia Ganz, MD, UCLA Jonsson Comprehensive Cancer Center, discusses a study comparing anastrozole versus tamoxifen in patients with ductal carcinoma in situ (DCIS) breast cancer.

Dr. Joanne Blum on the EMBRACA Trial in Metastatic BRCA-Mutant Breast Cancer

December 11th 2015

Joanne Blum, MD, PhD, oncologist with Texas Oncology and a member of the Breast Cancer Committee for The US Oncology Network, discuses the EMBRACA trial.

Buparlisib Modestly Improves PFS in HR-Positive Advanced Breast Cancer

December 11th 2015

Treatment with the PI3K inhibitor buparlisib plus fulvestrant showed a 1.9-month extension in progression-free survival compared with fulvestrant alone in women with endocrine-resistant HR-positive/HER2-negative advanced breast cancer.

APOBEC3B Overexpression Linked to Tamoxifen Resistance

December 11th 2015

The enzyme APOBEC3B has been associated with resistance to treatment with tamoxifen in retrospective studies and xenograft models of ER-positive breast cancer.

Estrogen Receptor Mutations Linked to Lower Survival in HR+/HER2- Breast Cancer

December 11th 2015

Estrogen receptor mutations are prevalent and associated with poorer survival in patients with pretreated HR+/HER2- metastatic breast cancer.

Study Links pCR After Neoadjuvant Therapy to Improved Survival in TNBC

December 10th 2015

Achieving a pCR with standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab was associated with a survival improvement in patients with triple-negative breast cancer.